In 2015, together with Daniel OLIVE and Alem TRUNEH, Benjamin CHARLES cofounded ImCheck Therapeutics.
He was a Board Member of the Company and its Chief Business Officer until June 2019.
In 2008, Benjamin CHARLES started his career in healthcare consulting and mergers & acquisitions, firstly at BNP Paribas Corporate Finance, and then at AEC Partners and Publicis Healthcare, Paris. Benjamin advised pharmaceuticals companies as well as SMEs on strategic planning, business development, market access, and medical affairs assignments. Benjamin joined Inserm Transfert in 2012 where he took responsibility for the oncology portfolio, out-licensing biomarkers and therapeutic compounds to pharmaceutical companies and startups, including in the fields of Immune-modulation and therapeutic antibodies.
Benjamin holds a doctorate in Pharmaceutical Sciences and an MBA from Essec Business School; he also is a member of the chair of bioethics and therapeutic innovation and of the chair Essec Santé.